Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients

Summary

Evaluation the efficacy and safety profile of trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia (PCP) prophylaxis in Patients With Connective Tissue Diseases (CTD) treated with high-dose glucocorticoids and immunosuppressive agents. Open-labeled, randomized, prospective single-center clinical trial. Observation period of 12 weeks.

Timeline

Start

2012-08

Primary completion

2013-06

Completion

2013-08

Drugs

Indications